Histamine-2-receptor antagonists and antacids in the critically ill population: stress ulceration versus nosocomial pneumonia.
We performed a meta-analysis to evaluate whether stress ulcer prophylaxis with histamine-2-receptor antagonists or antacids reduces mortality in critically ill patients. It appears that sucralfate results in a lower incidence of nosocomial pneumonia than either antacids or histamine-2-receptor antagonists. With respect to mortality, strong trends favored sucralfate over both antacids and histamine-receptor antagonists.
Cook
D J
DJ
Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Reeve
B K
BK
Scholes
L C
LC
D000863:Antacids / Q000627:therapeutic use*; D016638:Critical Illness / Q000401:mortality*; D003428:Cross Infection / Q000401:mortality; D006471:Gastrointestinal Hemorrhage / Q000209:etiology / Q000517:prevention & control; D006635:Histamine H2 Antagonists / Q000627:therapeutic use*; D006801:Humans; D010437:Peptic Ulcer / Q000209:etiology / Q000517:prevention & control*; D018410:Pneumonia, Bacterial / Q000401:mortality; D013312:Stress, Physiological / Q000150:complications*; D013392:Sucralfate / Q000627:therapeutic use
D000863:Antacids; D006635:Histamine H2 Antagonists; D013392:Sucralfate